气候变化领域集成服务门户(CCPortal): Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

CCPortal

DOI	10.1126/science.abh2315
	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
	Hastie K.M.; Li H.; Bedinger D.; Schendel S.L.; Moses Dennison S.; Li K.; Rayaprolu V.; Yu X.; Mann C.; Zandonatti M.; Avalos R.D.; Zyla D.; Buck T.; Hui S.; Shaffer K.; Hariharan C.; Yin J.; Olmedillas E.; Enriquez A.; Parekh D.; Abraha M.; Feeney E.; Horn G.Q.; Aldon Y.; Ali H.; Aracic S.; Cobb R.R.; Federman R.S.; Fernandez J.M.; Glanville J.; Green R.; Grigoryan G.; Lujan Hernandez A.G.; Ho D.D.; Huang K.-Y.A.; Ingraham J.; Jiang W.; Kellam P.; Kim C.; Kim M.; Kim H.M.; Kong C.; Krebs S.J.; Lan F.; Lang G.; Lee S.; Leung C.L.; Liu J.; Lu Y.; MacCamy A.; McGuire A.T.; Palser A.L.; Rabbitts T.H.; Tehrani Z.R.; Sajadi M.M.; Sanders R.W.; Sato A.K.; Schweizer L.; Seo J.; Shen B.; Snitselaar J.L.; Stamatatos L.; Tan Y.; Tomic M.T.; van Gils M.J.; Youssef S.; Yu J.; Yuan T.Z.; Zhang Q.; Peters B.; Tomaras G.D.; Germann T.; Saphire E.O.; CoVIC-DB team
发表日期	2021
ISSN	0036-8075
起始页码	478
结束页码	472
卷号	374 期号:6566
英文摘要	Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Multiple mutations in SARS-CoV-2 that could impair antibody defenses propagated in human-to-human transmission and spillover or spillback events between humans and animals. To develop prevention and therapeutic strategies, we formed an international consortium to map the epitope landscape on the SARS-CoV-2 spike protein, defining and structurally illustrating seven receptor binding domain (RBD)–directed antibody communities with distinct footprints and competition profiles. Pseudovirion-based neutralization assays reveal spike mutations, individually and clustered together in variants, that affect antibody function among the communities. Key classes of RBD-targeted antibodies maintain neutralization activity against these emerging SARS-CoV-2 variants. These results provide a framework for selecting antibody treatment cocktails and understanding how viral variants might affect antibody therapeutic efficacy. © 2021 American Association for the Advancement of Science. All rights reserved.
英文关键词	antibody; COVID-19; morbidity; mortality; neutralization; severe acute respiratory syndrome; SARS coronavirus
语种	英语
来源期刊	Science
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/243969
作者单位	Carterra, 825 N. 300 W. Ste C309, Salt Lake City, UT 84103, United States; Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Duke University, Durham, NC 27701, United States; Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, 1105 AZ, Netherlands; Quadrucept Bio, Ltd., Cambridge, CB23 6DW, United Kingdom; Myrio Therapeutics Pty, Ltd., 1 Dalmore Drive, Scoresby, VIC 3179, Australia; National Resilience, Inc., 13200 NW Nano Ct., Alachua, FL 32615, United States; Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, United States; Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, United States; Centivax, Inc., 201 Gateway Blvd., Floor 1, South San Francisco, CA 94080, United States; Twist Bioscience, 681 Gateway Blvd., South San Fr...
推荐引用方式 GB/T 7714	Hastie K.M.,Li H.,Bedinger D.,et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study[J],2021,374(6566).
APA	Hastie K.M..,Li H..,Bedinger D..,Schendel S.L..,Moses Dennison S..,...&CoVIC-DB team.(2021).Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.Science,374(6566).
MLA	Hastie K.M.,et al."Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study".Science 374.6566(2021).